OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Flt3 inhibitor AC220 is a potent therapy in a mouse model of myeloproliferative disease driven by enhanced wild-type Flt3 signaling
Samuel J. Taylor, Samantha A. Dagger, Christine B.F. Thien, et al.
Blood (2012) Vol. 120, Iss. 19, pp. 4049-4057
Open Access | Times Cited: 39
Samuel J. Taylor, Samantha A. Dagger, Christine B.F. Thien, et al.
Blood (2012) Vol. 120, Iss. 19, pp. 4049-4057
Open Access | Times Cited: 39
Showing 26-50 of 39 citing articles:
Dasatinib Targets B-Lineage Cells but Does Not Provide an Effective Therapy for Myeloproliferative Disease in c-Cbl RING Finger Mutant Mice
Johanna M. Duyvestyn, Samuel J. Taylor, Samantha A. Dagger, et al.
PLoS ONE (2014) Vol. 9, Iss. 4, pp. e94717-e94717
Open Access | Times Cited: 12
Johanna M. Duyvestyn, Samuel J. Taylor, Samantha A. Dagger, et al.
PLoS ONE (2014) Vol. 9, Iss. 4, pp. e94717-e94717
Open Access | Times Cited: 12
UNC5293, a potent, orally available and highly MERTK-selective inhibitor
Hongchao Zheng, Jichen Zhao, Bing Li, et al.
European Journal of Medicinal Chemistry (2021) Vol. 220, pp. 113534-113534
Closed Access | Times Cited: 11
Hongchao Zheng, Jichen Zhao, Bing Li, et al.
European Journal of Medicinal Chemistry (2021) Vol. 220, pp. 113534-113534
Closed Access | Times Cited: 11
Dasatinib promotes the activation of quiescent hematopoietic stem cells in mice
Johanna M. Duyvestyn, Samuel J. Taylor, Samantha A. Dagger, et al.
Experimental Hematology (2016) Vol. 44, Iss. 5, pp. 410-421.e5
Open Access | Times Cited: 10
Johanna M. Duyvestyn, Samuel J. Taylor, Samantha A. Dagger, et al.
Experimental Hematology (2016) Vol. 44, Iss. 5, pp. 410-421.e5
Open Access | Times Cited: 10
Sorafenib priming may augment salvage chemotherapy in relapsed and refractory FLT3-ITD-positive acute myeloid leukemia
Katherine D. Cummins, Stephen M. Jane, Slavisa Ninkovic, et al.
Blood Cancer Journal (2014) Vol. 4, Iss. 8, pp. e237-e237
Open Access | Times Cited: 8
Katherine D. Cummins, Stephen M. Jane, Slavisa Ninkovic, et al.
Blood Cancer Journal (2014) Vol. 4, Iss. 8, pp. e237-e237
Open Access | Times Cited: 8
Mouse models for pre-clinical drug testing in leukemia
Sanil Bhatia, Svenja Daschkey, Franziska Lang, et al.
Expert Opinion on Drug Discovery (2016) Vol. 11, Iss. 11, pp. 1081-1091
Closed Access | Times Cited: 6
Sanil Bhatia, Svenja Daschkey, Franziska Lang, et al.
Expert Opinion on Drug Discovery (2016) Vol. 11, Iss. 11, pp. 1081-1091
Closed Access | Times Cited: 6
Myelofibrosis: challenges for preclinical models and emerging therapeutic targets
Erika Morsia, Naseema Gangat
Expert Opinion on Therapeutic Targets (2021), pp. 1-12
Closed Access | Times Cited: 6
Erika Morsia, Naseema Gangat
Expert Opinion on Therapeutic Targets (2021), pp. 1-12
Closed Access | Times Cited: 6
Small Molecule Inhibitors of MERTK and FLT3 Induce Cell Cycle Arrest in Human CD8+ T Cells
Richard Powell, Marlies J. W. Peeters, Anne Rahbech, et al.
Vaccines (2021) Vol. 9, Iss. 11, pp. 1294-1294
Open Access | Times Cited: 6
Richard Powell, Marlies J. W. Peeters, Anne Rahbech, et al.
Vaccines (2021) Vol. 9, Iss. 11, pp. 1294-1294
Open Access | Times Cited: 6
The combination of FLT3 and SYK kinase inhibitors is toxic to leukaemia cells with CBL mutations
Ellen Weisberg, Chengcheng Meng, Abigail E. Case, et al.
Journal of Cellular and Molecular Medicine (2020) Vol. 24, Iss. 3, pp. 2145-2156
Open Access | Times Cited: 1
Ellen Weisberg, Chengcheng Meng, Abigail E. Case, et al.
Journal of Cellular and Molecular Medicine (2020) Vol. 24, Iss. 3, pp. 2145-2156
Open Access | Times Cited: 1
CBL mutations promote activation of PI3K/AKT signaling via LYN kinase
Roger Belizaire, Sebastian Koochaki, Namrata D. Udeshi, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2020)
Closed Access | Times Cited: 1
Roger Belizaire, Sebastian Koochaki, Namrata D. Udeshi, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2020)
Closed Access | Times Cited: 1
Étude de la voie HOX-Flt3 dans les leucémies de type pré-B induites par E2A-Pbx1
Gratianne Vaisson
(2014)
Closed Access
Gratianne Vaisson
(2014)
Closed Access
Functions of Novel Ligand-independent Flt3 Alleles and RANKL in Promoting Dissemination of Murine B-Cell Leukemias to the Central Nervous System
Eniko Papp
(2014)
Closed Access
Eniko Papp
(2014)
Closed Access
Membranes, molecules and biophysics: enhancing monocyte derived dendritic cell (MDDC) immunogenicity for improved anti-cancer therapy
Cyril Rauch, Hiba Ibrahim, Neil Foster
journal of cancer therapeutics and research (2013) Vol. 2, Iss. 1, pp. 20-20
Open Access
Cyril Rauch, Hiba Ibrahim, Neil Foster
journal of cancer therapeutics and research (2013) Vol. 2, Iss. 1, pp. 20-20
Open Access
Hitting the snooze button: Inducing quiescence with the FLT3 inhibitor quizartinib protects hematopoietic progenitors from chemotherapy
Samuel J. Taylor, Wallace Y. Langdon
Molecular & Cellular Oncology (2017) Vol. 4, Iss. 6, pp. e1378156-e1378156
Open Access
Samuel J. Taylor, Wallace Y. Langdon
Molecular & Cellular Oncology (2017) Vol. 4, Iss. 6, pp. e1378156-e1378156
Open Access
Sleeping through the storm: Preventing myelosuppression with quizartinib
Samuel J. Taylor, Wallace Y. Langdon
Oncotarget (2017) Vol. 8, Iss. 51, pp. 88255-88256
Open Access
Samuel J. Taylor, Wallace Y. Langdon
Oncotarget (2017) Vol. 8, Iss. 51, pp. 88255-88256
Open Access
